{"id":59063,"date":"2026-03-18T06:50:11","date_gmt":"2026-03-18T05:50:11","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/03\/18\/immune-dyshomeostasis-in-lifestyle-associated-diseases-a-new-paradigm-for-personalized-medicine-and-prevention\/"},"modified":"2026-03-18T06:50:11","modified_gmt":"2026-03-18T05:50:11","slug":"immune-dyshomeostasis-in-lifestyle-associated-diseases-a-new-paradigm-for-personalized-medicine-and-prevention","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/03\/18\/immune-dyshomeostasis-in-lifestyle-associated-diseases-a-new-paradigm-for-personalized-medicine-and-prevention\/","title":{"rendered":"Immune dyshomeostasis in lifestyle-associated diseases: a new paradigm for personalized medicine and prevention"},"content":{"rendered":"<div>\n<p><b>Curr Opin Immunol<\/b>. 2026 Mar 16;100:102754. doi: 10.1016\/j.coi.2026.102754. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Non-communicable diseases, including metabolic, inflammatory, and malignant disorders, now dominate global morbidity and mortality. These chronic, lifestyle-associated diseases expose the limits of strategies focused on suppressing late-stage inflammation. We argue that immune dyshomeostasis &#8211; rather than overt inflammation &#8211; represents the more actionable target in lifestyle-associated disease. Across barrier tissues, immune circuits involving innate lymphoid cells and epithelial mediators such as IL-22 preserve tissue resilience under environmental stress. Metabolic regulators, including itaconate-NRF2 signaling, further constrain inflammatory activation and reinforce immune balance. A homeostasis-first strategy emphasizes early detection of pathway drift using feasible biomarkers, assignment of corrective levers spanning lifestyle, exposure hygiene, and pharmacology, and longitudinal tracking of restoration using tissue-relevant endpoints. Proof-of-principle interventions, including immune reset in autoimmunity, demonstrate that immune set-points are druggable while underscoring the need for earlier interventions. Together, these concepts position immune homeostasis as a unifying framework for precision prevention and translational immunology.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41844070\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=8900118&amp;ff=20260318014958&amp;v=2.19.0.post6+133c1fe\">41844070<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.coi.2026.102754\">10.1016\/j.coi.2026.102754<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Curr Opin Immunol. 2026 Mar 16;100:102754. doi: 10.1016\/j.coi.2026.102754. Online ahead of print. ABSTRACT Non-communicable diseases, including metabolic, inflammatory, and malignant disorders, now dominate global morbidity and mortality. These chronic, lifestyle-associated diseases expose the limits of strategies focused on suppressing late-stage inflammation. We argue that immune dyshomeostasis &#8211; rather than overt inflammation &#8211; represents the more &#8230; <a title=\"Immune dyshomeostasis in lifestyle-associated diseases: a new paradigm for personalized medicine and prevention\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/18\/immune-dyshomeostasis-in-lifestyle-associated-diseases-a-new-paradigm-for-personalized-medicine-and-prevention\/\" aria-label=\"Read more about Immune dyshomeostasis in lifestyle-associated diseases: a new paradigm for personalized medicine and prevention\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[59,42],"tags":[],"class_list":["post-59063","post","type-post","status-publish","format-standard","hentry","category-current-opinion-in-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/59063","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=59063"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/59063\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=59063"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=59063"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=59063"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}